Medifast (NYSE:MED) Third Quarter 2022 Results
Key Financial Results
Revenue: US$390.4m (down 5.6% from 3Q 2021).
Net income: US$36.2m (down 14% from 3Q 2021).
Profit margin: 9.3% (in line with 3Q 2021).
EPS: US$3.30 (down from US$3.59 in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medifast Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 71%.
Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 8.7% growth forecast for the Personal Products industry in the US.
The company's shares are down 7.9% from a week ago.
It is worth noting though that we have found 3 warning signs for Medifast (2 shouldn't be ignored!) that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here